scispace - formally typeset
R

Ryan Zarychanski

Researcher at University of Manitoba

Publications -  230
Citations -  12857

Ryan Zarychanski is an academic researcher from University of Manitoba. The author has contributed to research in topics: Randomized controlled trial & Medicine. The author has an hindex of 48, co-authored 193 publications receiving 9665 citations. Previous affiliations of Ryan Zarychanski include Winnipeg Regional Health Authority & McGill University.

Papers
More filters
Journal ArticleDOI

Re-framing the question: Should hydroxyethyl starch be used in clinical practice?

TL;DR: Two studies published in this issue of the Journal show how HES use changed following the Health Canada warning, and what the clinical impact of HES de-investment was in cardiac surgery.
Journal ArticleDOI

Effectiveness of evidence-based treatments of fetal alcohol spectrum disorders in children and adolescents: a systematic review protocol.

TL;DR: A protocol for a systematic review assessing the effectiveness of evidence from randomised controlled trials comparing fetal alcohol spectrum disorders pharmacological and non-pharmacological interventions with placebo/dummy interventions or usual standards of care in children and adolescents (<18 years old is provided.
Journal ArticleDOI

Association of Hydroxyethyl Starch Administration With Mortality and Acute Kidney Injury in Critically Ill Patients Requiring Volume Resuscitation: A Systematic Review and Meta-Analysis

TL;DR: Clinical trials and systematic reviews have suggested a greater incidence of renal damage and mortality in patients receiving hydroxyethyl starch, but these findings have been inconsistent.
Journal ArticleDOI

Osteonecrosis of the Jaw Associated with Pamidronate Therapy.

TL;DR: Osteonecrosis of the jaw is an important adverse outcome associated with bisphosphonate therapy and the unremitting nature of this clinical development, and the long lasting morbidity associated with it suggests that patients should be counseled regarding the possible occurrence of oste onecrosis prior to initiating therapy with pamidronate.